A recent elegant study that evaluated the prevalence of FH as detected through universal screening and highlighted the utility of reversecascade screening to identify affected parents McCrindle BW, Urbina EM, Dennison BA, et al Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing Circulation 2007;115:1948–1967 A scientific statement from the American Heart Association summarizing current recommendations regarding drug therapy for high-risk lipid abnormalities in the pediatric population Braamskamp M, Langslet G, McCrindle BW, et al Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study Circulation 2017;136:359–366 A recent important study demonstrating the slowing of progression of cIMT in statin-treated children with FH, resulting in no significant difference in cIMT between FH-affected children and their unaffected siblings after 2 years Raal FJ, et al PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Lancet 2015;385(9965):331–340 The RUTHERFORD-2 Trial: This placebocontrolled RCT study of adults with heterozygous FH, treatment with evolocumab (a PCSK9 inhibitor) resulted in significant reductions in mean LDL-C concentrations and was well tolerated Sabatine MS, et al Evolocumab and clinical outcomes in patients with cardiovascular disease N Engl J Med 2017;376(18):1713– 1722 In this randomized, double-blind, placebocontrolled trial (FOURIER) involving 27,564 adults with atherosclerotic cardiovascular disease, evolocumab resulted in a significant reduction in a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization Magge SN, Goodman E, Armstrong SC The metabolic syndrome in children and adolescents: shifting the focus to cardiometabolic risk factor clustering Pediatrics 2017 [Epub ahead of print] An excellent review summarizing the difficulties in diagnosing the metabolic syndrome in childhood with an emphasis on shifting the focus to identifying and treating individual cardiovascular risk factors Mitchell GF, Hwang SJ, Vasan RS, et al Arterial stiffness and cardiovascular events: the Framingham Heart Study Circulation 2010;121:505–511 This important study demonstrated pulse wave velocity to be predictive of major cardiovascular disease events, independent of other CVRFs Townsend RR, et al Recommendations for improving and standardizing vascular research on arterial stiffness: a scientific statement from the American Heart Association Hypertension 2015;66(3):698–722 A scientific statement from the American Heart Association on improving vascular research on arterial stiffness Urbina EM, Williams RV, Alpert BS, et al Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the ... metabolic syndrome in children and adolescents: shifting the focus to cardiometabolic risk factor clustering Pediatrics 2017 [Epub ahead of print] An excellent review summarizing the difficulties in diagnosing the metabolic syndrome in childhood